PIMREG and chronic kidney disease: As pharmacological Cat-S inhibition has been shown to prevent macrovascular and microvascular disease in experimental animal models, there appears to be a valid scientific rationale to study whether Cat-S is associated with adverse outcomes in CKD and whether its inhibition can reduce cardiovascular morbidity and mortality in CKD patients.